Zim focuses on multiple business aspects & multi-pronged growth strategy for sustained progress.
Focus on developing new delivery solutions for generic products which
Enhance product life cycle
Increase patient convenience
Improved adherence in treatement
Improved adherence in treatement
with priority on certain therapeutic segments.
Alternate drug delivery solution for generic pharmaceutical & nutraceutical products (prescription & OTC)
Step up direct marketing:
Hire senior marketing professionals for developing marketing partnerships in finished formulations and semi-finished products across RoW markets.
Invest in product registration & marketing partnerships that allow ZIM to capture value of brands and better margins.
Invest in R&D with focus on entering developed markets
Equipment, team, studies, processes & systems.
Facilities to develop a pipeline of products valuable to business partners & patients across markets (co-development & own new product alternatives) with specific focus on entering developed markets.
Add small batch manufacturing (SBM) facilities for promoting the formulations business & supporting clients across markets with small but high value order quantities including technology transfer from R&D.
Focus on developing new delivery solutions for generic products which:
Continue strengthening R&D capabilities – Increase investment in R&D as % of sales.
Acquire scientists, formulators, analysts & add higher end scientific equipment to the existing R&D centre.
Invest in various pilot, pivotal stability and BE studies (own & under co-development) to enhance development process, audit trails, dossier readiness, filings & registrations.
Partnering with non-infringing API producers for developing products to be launched in EM.
Hire experienced R&D professionals to lead product development, various studies, dossier readiness, filings, registration and launch of products in U.S.A / Developed Markets; with expertise for product registrations from U.S.A FDA, MHRA UK, ANVISA, etc.
The OTF R&D Centre to initiate independent contract research operations for other pharmaceutical companies in regulated markets.
Invest in pilot, pivotal and bio-equivalence studies (Under Co-Development).
R&D centre to eventually launch products in Developed Markets – key target being USA (prescription and OTC products) with immediate focus being on “emerging and RoW markets”.
New Drug Delivery Platforms (MUPS, Patches etc.) to be developed at this R&D centre.
Invest in team and processes for development of dossiers and product registration/filings across markets.
Strengthen core PFI business with focus on developing a pipeline of high margin products.
Enter into local marketing tie-ups and new partnerships in new geographies like LATAM, CIS and MENA
ZIM ventured into Sri Lanka directly for differentiated formulations in FY 2011.
Products were jointly developed in consultation with Sri Lankan partners & supplied in finished dosage form, including ready to market packaging and the registrations of the product with the partner. The business in Sri Lanka grew 12x over the last 6 years from INR 10 Million in FY11 to INR 127 Million in FY17 with a CAGR of over 50%.
ZIM plans to replicate the Sri Lankan model in other regions and introduce high margin differentiated generic formulations in RoW and Emerging Markets – MENA, SA, SEA, CIS & LATAM.
Enter into marketing joint venture arrangements, partnerships, authorisations for specific markets to capture more of the value chain in terms of brand registrations and improved margins.
Focus on new product development and product life extensions for original product manufacturers (OPMs).
Enter into long term licensing agreements with OPM and other players to co-develop their existing products in OTF format.
Plans to enter into developed markets (US, EU, JAPAN) in partnership with OPMs over time.
Register the OTF product in RoW and emerging markets under its brand and market through partnership with local players.
Set-up dedicated small batch manufacturing (SBM) facility for manufacturing pellets, tablets & granules to bring about.
Flexibility in manufacturing for pre-formulation and formulation for exports and,
Unlock capacity constraint in existing plant.
Internal reorganisation & upgrading of certain facilities for improved audit and compliance.
Investment in equipment and more experienced manpower.
Invest in ERP for integrated software that covers operations & financial processes in line with requirements of developed markets.
Dr. Anwar S. Daud
Chairman and Managing Director
Dr. Anwar Daud, PhD. (Pharmaceutical Sciences), M. Pharm. (Medicinal Chemistry) from
Nagpur University (1983), promoted ZIM in 1989.
Director - Finance
Mr. Zulfiquar Kamal is a chartered accountant and has been associated with the company for over 25 years.
Mr. Prakash Sapkal is a Pharmacy graduate with post-graduation in Business Administration and has been associated with the Company for 24 years.
Senior Vice President – Technical Services
Mr Vijay Fudke is a pharmacy graduate with an association of more than 20 years with ZIM.
Director - Business Development
Mr. Niraj Dhadiwal is a pharmacy graduate with a diploma in business management and has been with the company for nearly three decades.
Director - Administration
Mr Riaz Kamal has been associated with the company since inception.
Senior Vice President – Operations
Mr Pradeep Kataria is a postgraduate in pharmacy with an association of more than 21 years with the organization.
Over the last 4 years, high margin business (>50% gross margin) has seen a CAGR of 20%
(growing 1.7x) compared to a drop of 17% CAGR in the low margin business during the same period. The strategy for improving margins and consequently better return from capital employed has been driven primarily on account of:
Focused marketing efforts on direct exports of PFI.
Reducing low margin deemed exports business-particularly from Africa.
Direct bidding for higher margin products in.
Government tenders vs. bidding through third parties.
‘Commercialization’ of the OTF range of products.
STANDALONE HALF YEARLY INCOME STATEMENTS FY 2018
STANDALONE YEARLY INCOME STATEMENTS
STANDALONE YEARLY STATEMENTS OF FINANCIAL POSITION
INVESTOR REPORTS & PRESENTATIONS
- ANNUAL RESULTS
- QUARTERLY RESULTS
- ANNUAL REPORTS
- SHAREHOLDING PATTERN
- STATUTORY COMMUNICATIONS
ANNUAL FINANCIAL RESULTS
QUARTERLY FINANCIAL RESULTS
Our Quarterly Financials
QUARTERLY FINANCIAL RESULTS - Q1 - 2018 - 19
QUARTERLY FINANCIAL RESULTS - Q4 - 2017 - 18
QUARTERLY FINANCIAL RESULTS - Q3 - 2017 - 18
We are pleased to present to you ZIM Laboratories Limited Annual Reports.
Our Shareholding Patterns
MR. PIYUSH NIKHADE
Sadoday Gyan (Ground Floor)
Opp. NADT, Nelson Square,
Nagpur – 440013